Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Smith & Nephew reveals collusion attempt

This article was originally published in The Gray Sheet

Executive Summary

Smith & Nephew discloses July 31 that one of its independent sales representatives sent an email Oct. 28, 2005, to competitors seeking cooperation on pricing for hip and knee implants. The London-based firm, which has since severed its relationship with the rep, denies authorizing or acting upon the email. The price-fixing scheme likely prompted an investigation by the U.S. Department of Justice, which subpoenaed Smith & Nephew, Stryker, Johnson & Johnson/DePuy, Biomet and Zimmer in June for documents related to possible antitrust violations (1"The Gray Sheet" July 3, 2006, p. 8). A separate investigation by the U.S. attorney's office in Newark, N.J., pertaining to the relationship between orthopedics manufacturers and physicians is ongoing (2"The Gray Sheet" April 4, 2005, p. 3)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel